Table 2.
Unadjusted 24-week relapse rates of the overall sample and by randomized treatment assignment for the intent to treat and per protocol sample
| Overall | Naltrexone | Buprenorphine | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sample | N | % Not Relapsed | N | % Relapsed | N | % Not Relapsed | N | % Relapsed | N | % Not Relapsed | N | % Relapsed |
| ITT | (N=570) | (N=283) | (N=287) | |||||||||
| ≤25 | 33 | 29.7 | 78 | 70.3 | 16 | 32.7 | 33 | 67.3 | 17 | 27.4 | 45 | 72.6 |
| >25 | 189 | 41.2 | 270 | 58.8 | 82 | 35.0 | 152 | 65.0 | 107 | 47.6 | 118 | 52.4 |
| Per protocol | (N=474) | (N=204) | (N=270) | |||||||||
| ≤25 | 33 | 33.7 | 65 | 66.3 | 16 | 40.0 | 24 | 60.0 | 17 | 29.3 | 41 | 70.7 |
| >25 | 185 | 49.2 | 191 | 50.8 | 82 | 50.0 | 82 | 50.0 | 103 | 48.6 | 109 | 51.4 |